Byung Chul Lee,Sang Eun Kim,Ji Sun Kim,Byung Seok Moon,Jae Ho Jung
申请号：
US13699511
公开号：
US09439986B2
申请日:
2011.05.24
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the present invention has a high subnanomolar affinity to integrin αvβ3 (also called as a vitronectin receptor) that is activated in an angiogenic action induced by a tumor, and acts exclusively upon cancer cells having selectively activated integrin αvβ3 because of a substantially low intake into the liver and intestines.
